Sprint Bioscience AB (5JA1)
XMUN XFRA Primary XMUN Summary
5JA1 Chart
Sprint Bioscience AB (5JA1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sprint Bioscience AB ever had a stock split?
Sprint Bioscience AB Profile
| Biotechnology Industry | Healthcare Sector | Johan Emilsson CEO | XMUN Exchange | SE0006343745 ISIN |
| Sweden Country | 36 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Sprint Bioscience AB (publ), established in 2009 and based in Huddinge, Sweden, stands as a notable entity within the pharmaceutical domain, particularly focusing on the development of innovative pharmaceutical products aimed at combating cancer. The company distinguishes itself by emphasizing research and development in cancer treatments, with a keen focus on leveraging immunotherapies and addressing tumor metabolism, non-alcoholic steatohepatitis (NASH), and diabetes. Sprint Bioscience's dedication to innovation in oncology treatment underscores its commitment to advancing healthcare solutions and improving patient outcomes in Sweden and potentially globally.
Products and Services
- VPS34:
This drug candidate represents Sprint Bioscience's venture into utilizing immunotherapy for treating various types of cancer. VPS34 operates by targeting specific mechanisms within the body’s immune system, aiming to enhance the body’s ability to fight cancer. This pioneering approach underlines the company's dedication to formulating next-generation cancer therapies.
- PETRA01:
Another noteworthy drug candidate, PETRA01, has been meticulously developed for the treatment of cancer. This development emphasizes Sprint Bioscience’s relentless pursuit of groundbreaking solutions in the field of oncology, aiming to introduce novel treatments that can significantly improve cancer care.
